This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2026 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.70% per year. These returns cover a period from January 1, 1988 through April 6, 2026. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View the Zacks #1 Rank List
biotechs: Archive
Silver Economy Investing: Why the Healthcare Giants Are in Focus
by Urmimala Biswas
Healthcare giants like Eli Lilly, Tandem Diabetes, Intuitive Surgical and ResMed are tapping aging-driven demand in obesity, surgery and sleep care.
ABTNegative Net Change LLYPositive Net Change MDTPositive Net Change ISRGNegative Net Change RMDNegative Net Change TNDMNegative Net Change
biotechs cell-therapy healthcare medical medical-devices pharmaceuticals
Is it Time to Exit ADMA Biologics Stock After a 22% Monthly Plunge?
by Ekta Bagri
ADMA shares plunge after the company cuts 2026 guidance, citing pricing pressure, rising competition and elevated IG channel inventories.
GRFSNegative Net Change ADMANegative Net Change TAKNegative Net Change
biotechnology biotechs medical pharmaceuticals
Regeneron & Parabilis Sign Oncology Collaboration Worth Up to $2.2B
by Zacks Equity Research
REGN teams up with Parabilis in a potential $2.2B deal to develop Antibody-Helicon Conjugates targeting hard-to-treat cancers.
REGNNegative Net Change BMYNegative Net Change MRKPositive Net Change BAYRYNegative Net Change
biotechnology biotechs medical pharmaceuticals
BMRN Stock Down on Mixed Results From Rare Disease Therapy Study
by Zacks Equity Research
BioMarin shares fall after BMN 401 meets a biomarker goal but misses a key radiographic endpoint in a late-stage ENPP1 deficiency study.
BMRNNegative Net Change IMCRNegative Net Change INDVPositive Net Change
biotechs medical
Can Intellia's Pipeline Push Drive Long-Term Growth Amid Rivalry?
by Kanishka Das
NTLA advances late-stage studies for nex-z and starts FDA filing for lonvo-z, positioning its pipeline for potential long-term growth.
REGNNegative Net Change BEAMPositive Net Change NTLAPositive Net Change CRSPPositive Net Change
biotechs
FDA Accepts Viatris' NDA for Fast-Acting Non-Opioid Pain Therapy
by Zacks Equity Research
VTRS' fast-acting meloxicam NDA enters FDA review as a non-opioid acute pain therapy, with a decision expected by Dec. 27, 2026.
LQDANegative Net Change VTRSPositive Net Change IMCRNegative Net Change INDVPositive Net Change
biotechnology biotechs medical pharmaceuticals
FDA Grants Priority Tag to Bayer's Oncology Drug for First-Line NSCLC
by Zacks Equity Research
BAYRY wins FDA priority review for sevabertinib in first-line HER2-mutant NSCLC, building momentum for the oral TKI.
BAYRYNegative Net Change LQDANegative Net Change IMCRNegative Net Change INDVPositive Net Change
biotechs
ImmunityBio Secures Five U.S. Patents for Anktiva in Bladder Cancer
by Zacks Equity Research
IBRX secures five U.S. patents for Anktiva in bladder cancer, extending franchise protection through 2035 amid strong sales growth.
IMCRNegative Net Change IBRXNegative Net Change INDVPositive Net Change
biotechs medical
Bayer Gets FDA Priority Review for Asundexian NDA in Stroke Prevention
by Zacks Equity Research
BAYRY gains FDA Priority Review for asundexian NDA after phase III data showed a 26% cut in ischemic stroke risk without more major bleeding.
BAYRYNegative Net Change LQDANegative Net Change IMCRNegative Net Change INDVPositive Net Change
biotechnology biotechs medical pharmaceuticals
Regeneron's Late-Stage Melanoma Study Misses Primary Goal
by Zacks Equity Research
REGN's melanoma combo misses the primary endpoint in a phase III study despite longer median PFS versus Keytruda monotherapy.
REGNNegative Net Change BMYNegative Net Change MRKPositive Net Change
biotechnology biotechs medical pharmaceuticals